Cost Action GenE-Humdi @GeneHumdi

Joined January 2023

Tweets

426
Followers

205
Following

140
Likes

238

Cost Action GenE-Humdi @GeneHumdi

a week ago

🌍 The GeneHumdi Annual Meeting 2026 brought together leading international experts in genome editing, advanced therapies and translational biomedicine at GENYO, in Granada, from May 26th to 28th. @genyo_pts instagram.com/reel/DZmijcaMG…

0 1 1 68 0

View Details

Cost Action GenE-Humdi @GeneHumdi

a week ago

4/4 More details: medium.com/p/d887f34864b3… Apply here: forms.gle/arqXtPJBMxCw5e… Looking forward to receiving your abstracts. #LipidNanoparticles #RNADelivery #Nanomedicine #TargetedDelivery #COSTAction #VirtualConference #PhD #Postdoc #EarlyCareerResearchers

0 1 1 51 0

View Details

Cost Action GenE-Humdi @GeneHumdi

a week ago

3/4 With the support and collaboration of: Dr. Maria Cristina Vinci, Cardiovascular Epigenetics Lab, Milan, Italy. Dr. Claudio Mussolino, Genome & Epigenome Engineering Lab, Freiburg, Germany.

1 1 1 39 0

View Details

Cost Action GenE-Humdi @GeneHumdi

a week ago

1/4🔬Excited to announce the COST-funded Virtual Conference on “Lipid Nanoparticles: From Fundamentals to Targeted Delivery”. Submit you abstract for flash presentations on lipid nanoparticles, RNA delivery, nanomedicine, and targeted therapeutics.

1 0 2 38 0

View Details

Cost Action GenE-Humdi @GeneHumdi

4 weeks ago

Cecilia Jimenez presented #EGMEDC, a new initiative to foster communication and exchange between #Genomeediting Clinicians, Healthcare Institutions and regulatory keyholders.

0 0 0 46 0

View Details

Cost Action GenE-Humdi @GeneHumdi

4 weeks ago

at the @GeneHumdi #Granada2026 #AnnualMeeting Gloria Gonzalez-Aseguinolaza @ggasegui Invited GenE-HumDi members to join the @ESGCT and offered to provide forums to keep and extend the collaborative networks started by our Action.

0 0 1 29 0

View Details

Cost Action GenE-Humdi @GeneHumdi

4 weeks ago

Jennifer Stott @idtdna opened the second session presenting: "From Target Discovery to Treatment: How IDT is Enabling CRISPR Medicine" showcasing a thorough toolkit to help #GenomeEditing

0 1 1 193 0

View Details

Cost Action GenE-Humdi @GeneHumdi

4 weeks ago

Day3 of the @GeneHumdi #Granada2026 #AnnualMeeting is about to start chaired by Alessia Cavazza and Karim Benabdellah

2 0 0 56 0

View Details

Cost Action GenE-Humdi @GeneHumdi

4 weeks ago

@COSTprogramme @DuskoLainscek @lentistem @Joanna_Vella @LedererCarsten Disemination Leader @tweet_Javi Ended the session. Notably, Raquel Soriano explained about the @COSTprogramme reimbursement for invited members

0 0 0 18 0

View Details

Cost Action GenE-Humdi @GeneHumdi

4 weeks ago

@COSTprogramme @DuskoLainscek @lentistem We also have the updates from Alessia Cavazza and Joanna Vella @Joanna_Vella, Carsten Lederer @LedererCarsten

1 0 0 15 0

View Details

Cost Action GenE-Humdi @GeneHumdi

4 weeks ago

@LedererCarsten Now we turn our attention towards the children with the need of receiving #GenomeEditing therapies. Viviana Giannuzzi presents "Genome editing therapies for children"

1 1 1 117 0

View Details

Cost Action GenE-Humdi @GeneHumdi

4 weeks ago

@LedererCarsten Next Emmely de Vries is connecting from The Netherlands to disvuss: "Regulatory aspects of ATMP development and marketing authorization (TBC)"

1 1 1 199 0

View Details

Cost Action GenE-Humdi @GeneHumdi

4 weeks ago

The afternoon session highlights #Regulatory, #PatientAccess and #SocialImpact, and it is chaired by Carsten Lederer and Zoltan Ivics ..

1 0 2 178 0

View Details

Cost Action GenE-Humdi @GeneHumdi

4 weeks ago

After a nice Poster session at the entrance of @genyo_pts the @GeneHumdi #Granada2026 #AnnualMeeting goes on

0 0 3 45 1

View Details

Cost Action GenE-Humdi @GeneHumdi

4 weeks ago

Closing this session Ignacio Perez de Castro @IPdC1 is giving us a short report to on CRISPR mediated therapies for "LMNA muscular dystrophy".

0 0 0 41 1

View Details

Cost Action GenE-Humdi @GeneHumdi

4 weeks ago

closing the presentations Alicia Roig-Merino @MaxCyte_info is presenting a professional safety assessment pipeline: "SeQure the win: off-target risk assessment for ATMPs in Europe "